The Vanguard Network will host its 6th Life Sciences CEO Forum, “Seeing Around Corners,” on November 17, 2025, from 2:30 PM to 7:00 PM EST at Foley & Lardner LLP, Boston, MA.

The Vanguard Network is pleased to announce that Judy Gawlik Brown, Board Member at Belden Inc., will serve as Session Leader for the upcoming Risk Management Exchange, taking place January 15, 2026, from 11:00 AM to 12:30 PM EST.

The Vanguard Network is pleased to announce that Bruno Cova, partner (shareholder) at Greenberg Traurig and one of Europe’s foremost authorities on corporate governance and risk, will join Ken Banta, Founder and CEO of The Vanguard Network, as co-leader of the next Risk Management Network session, “When the C-Suite Crosses the Line: Managing Leadership and Reputational Risk.”

The Vanguard Network will host its next General Counsel Forum, “Seeing Around Corners: The Transforming Role of the General Counsel,” on October 27, 2025, at Dentons US LLP in Chicago.

The Vanguard Network will host a virtual Unlocking Leadership conversation titled “Navigating the FDA as a Strategic Imperative” on October 24, 2025, from 11:30 AM to 12:30 PM EDT.

The Vanguard Network will hold a virtual executive exchange, Managing Risk at the Top: How To Plan for and Mitigate the Human Factor of CEO and C-suite Misbehavior, on October 23, 2025, from 11:00 AM to 12:30 PM EDT.

The Vanguard Network will convene senior executives for an invitation-only working breakfast on October 9, 2025, at APCO, 1250 Broadway, New York, to explore The Evolving Landscape of Shareholder Activism.

On September 30, 2025, The Vanguard Network launched the inaugural module of its Next Gen GC Program in Washington, DC.

The Vanguard Network announced today that its CEO and founder, Ken Banta, facilitated a dynamic discussion at The Nantucket Project event in New York City.

The Vanguard Network is proud to announce that Pharmaceutical Executive highlighted its Life Sciences CEO Forum, held on May 21, 2024, in Boston, in a feature article titled “Seeking Sustainable Solutions: Can Passion and Profit Coexist in Pharma ESG Efforts?”